Clinical Trials Browser

Lymphoproliferative Disorders × Nivolumab × Clear all

NCT03258567 2026-03-06

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Phase 2 Recruiting

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT02973113 2021-07-21

PREVALE

Phase 1 Completed

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders